Lana Pine

Robert F Spiera, MD, explains background mycophenolate treatment and its associated improved outcomes in patients with systemic sclerosis receiving lenabasum.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending November 19, 2021.

Kelly Gavigan, MPH, discusses the changes in patient-reported outcome scores during the COVID-19 pandemic.

Eric Morand, MD, discusses “Attainment of the Lupus Low Disease Activity State in Response to Anifrolumab in 2 Phase 3 Trials.”

Rheumatoid arthritis is a complex condition. How much do you know about RA treatment?

Jeffrey Curtis, MD, MS, MPH, discusses malignancies in older patients with rheumatoid arthritis and cardiovascular risks being treated with either tofacitinib or tumor necrosis factor (TNF) inhibitors.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending November 12, 2021.

Jeff Peterson, MD, discusses his study determining the complete response rate of pegloticase in conjunction with methotrexate.

Hermine Brunner, MD, MSc, MBA, discusses secukinumab treatment in patients with enthesitis-related arthritis and juvenile psoriatic arthritis.

Kyriakos A. Kirou, MD, DSc, FACP, explains the key findings of his upcoming ACR presentation, “COVID-19 Vaccine Antibody Responses in Patients Treated with B-Cell Agents Depend on B-Cell Counts at Time of Vaccine.”

"The primary efficacy endpoint was the proportion of patients with disease control without other immunosuppressants and prednisone-equivalent dose of ≤5 mg/day at week 52," Aranow stated.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending November 5, 2021.

Kazuki Yoshida, MD, MPH, ScD, discusses his ACR presentation entitled, “Comparative Safety of Gout "Treat-to-target" and "Usual Care" Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Causal Inference Approach.”

While approximately 80% of patients with rheumatic disease showed humoral immune response rates following the second dose of the COVID-19 vaccine, these numbers were significantly lower than controls.

Laure Gossec, MD, PhD discusses the association between improvements in patient-reported outcomes and disease activity in patients with psoriatic arthritis.

Investigators analyzed comorbidities, such as diabetes, which has been historically associated with gout, to determine what role, if any, they played in increasing the risk of lower extremity amputation.

Vibeke Strand, MD, explores her ACR presentation, “Assessing the Relationship of Patient Global Assessment of Disease Activity and Health Related Quality of Life by SF-36 with Other Patient-Reported Outcomes in Rheumatoid Arthritis: Post Hoc Analyses of Data from Phase 3 Trials of Baricitinib.”

Niti Goel, MD, discusses her ACR Convergence presentation entitled, “Depletion of KLRG1+ T Cells in a First-in-human Clinical Trial of ABC008 in Inclusion Body Myositis (IBM).”

Aaron Broadwell, MD, discusses his upcoming ACR study entitled, “Concomitant immunomodulation and pegloticase therapy: experiences with a variety of immunomodulatory agents in two community rheumatology practices.”

Joshua Solomon, MD, discusses his upcoming ACR presentation entitled, “A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease.”

Jean Liew, MD, MS, discusses her upcoming ACR Convergence presentation entitled, “SARS-CoV-2 Infections Among Vaccinated Individuals with Rheumatic Disease: Results from the COVID-19 Global Rheumatology Alliance Provider Registry."

Karen H. Costenbader, MD, MPH, discusses her upcoming ACR Convergence presentation entitled, “Year in Review: Clinical Rheumatology."

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending October 29, 2021.

Cassandra Calabrese, DO, examines immunopathogenesis, immunomodulation, COVID-19 vaccinations, and pre-exposure prophylaxis.

“Systemic lupus erythematosus is a chronic inflammatory autoimmune disease where a variety of organ complications contribute to an increased risk of premature mortality,” investigators stated.

Interview questions focused on mental and physical health, guidance received by healthcare providers, and the impact of COVID-19 on healthcare access and self-management behaviors.

“Using the strengthening exercises with mHealth may have the potential to reduce pain, improve mobility, functional activity, and activities of daily living among knee osteoarthritis patients who are overweight or obese," investigators stated.

Chronic back pain, a common symptom of axial spondyloarthritis that increases disease burden and reduces quality of life, may be improved by subcutaneous injection of secukinumab 150 mg or 300 mg.

On this month's episode of Overdrive, E Michael Lewiecki, MD, discusses recent controversies and trends in osteoporosis management, predictions for 2022, and how COVID-19 impacted the treatment landscape for rheumatologists.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending October 22, 2021.